Meiragtx Holdings Plc (MGTX)
NASDAQ:MGTX
Top Page
Meiragtx Holdings
(NASDAQ:MGTX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$7.50
▲(1.21% Upside)
Action:ReiteratedDate:01/04/26
The score is held down primarily by weak financial performance (declining revenue, heavy losses, high leverage/negative equity, and negative cash flows) and bearish technical signals. Offsetting these risks, recent corporate events—especially the Eli Lilly collaboration and the share repurchase/lock-up—provide meaningful strategic and financing support.
Positive Factors
Strategic Collaboration
The collaboration with Eli Lilly provides a $75 million upfront payment and potential milestone payments, enhancing MeiraGTx's revenue streams and solidifying its leadership in genetic medicine.
Negative Factors
Financial Instability
The negative equity and high leverage indicate financial instability, which can hinder MeiraGTx's ability to invest in R&D and limit operational flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Collaboration
The collaboration with Eli Lilly provides a $75 million upfront payment and potential milestone payments, enhancing MeiraGTx's revenue streams and solidifying its leadership in genetic medicine.
Read all positive factors
Meiragtx Holdings (MGTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$613.34M
Dividend YieldN/A
Average Volume (3M)341.94K
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue Growth96.83%
EPS Growth-61.92%
CountryUS
Employees375
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding80,490,890
10 Day Avg. Volume395,771
30 Day Avg. Volume341,939
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)6.27
Price to Sales (P/S)12.78
P/FCF Ratio-3.89
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue25.04
Enterprise Value/Gross Profit61.06
Enterprise Value/Ebitda-4.78
Forecast
1Y Price Target
$14.00Price Target Upside88.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.13
Revenue Forecast (FY)$124.69M
Meiragtx Holdings Business Overview & Revenue Model
Company Description
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia fo...
How the Company Makes Money
Meiragtx Holdings generates revenue primarily through the development and commercialization of its gene therapy products. The company earns money by conducting clinical trials and subsequently bringing successful therapies to market, which can lea...
Meiragtx Holdings Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
25
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.42M | 33.28M | 14.02M | 15.92M | 37.70M | 15.56M |
| Gross Profit | 11.24M | 9.49M | 14.02M | 15.92M | 37.70M | 15.56M |
| EBITDA | -143.50M | -121.69M | -57.05M | -116.07M | -71.40M | -53.68M |
| Net Income | -168.69M | -147.79M | -84.03M | -129.62M | -79.56M | -57.99M |
Balance Sheet | ||||||
| Total Assets | 189.47M | 269.75M | 326.74M | 318.24M | 320.16M | 363.70M |
| Cash, Cash Equivalents and Short-Term Investments | 14.84M | 103.66M | 129.57M | 115.52M | 137.70M | 209.52M |
| Total Debt | 88.06M | 84.80M | 89.26M | 92.25M | 23.73M | 22.25M |
| Total Liabilities | 230.03M | 201.92M | 188.57M | 200.50M | 134.76M | 125.14M |
| Stockholders Equity | -40.56M | 67.83M | 138.18M | 117.74M | 185.40M | 238.56M |
Cash Flow | ||||||
| Free Cash Flow | -121.04M | -109.45M | -125.54M | -118.06M | -65.75M | -100.99M |
| Operating Cash Flow | -116.27M | -104.50M | -105.36M | -73.10M | -10.53M | -63.97M |
| Investing Cash Flow | -4.24M | 23.48M | 34.03M | -44.96M | -61.72M | -37.02M |
| Financing Cash Flow | 11.19M | 54.53M | 84.02M | 95.20M | 1.71M | 82.73M |
Meiragtx Holdings Technical Analysis
Negative
7.41
Price Trends
7.57
Negative
7.87
Negative
7.83
Negative
Market Momentum
-0.04
Negative
47.91
Neutral
36.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGTX, the sentiment is Negative. The current price of 7.41 is below the 20-day moving average (MA) of 7.49, below the 50-day MA of 7.57, and below the 200-day MA of 7.83, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 47.91 is Neutral, neither overbought nor oversold. The STOCH value of 36.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MGTX.
Meiragtx Holdings Risk Analysis
Meiragtx Holdings disclosed 79 risk factors in its most recent earnings report. Meiragtx Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Meiragtx Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $4.97B | -8.47 | -32.00% | ― | ― | 45.66% | |
52 Neutral | $5.62B | -6.99 | -29.95% | ― | ― | 12.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.32B | -16.13 | -56.64% | ― | -36.36% | -945.72% | |
49 Neutral | $504.39M | -3.10 | -47.27% | ― | ― | ― | |
47 Neutral | $613.34M | -3.30 | -1065.47% | ― | 96.83% | -61.92% |
* Healthcare Sector Average
MGTX
Meiragtx Holdings
7.62
0.39
5.39%
TSHA
Taysha Gene Therapies
4.58
2.78
154.44%
FDMT
4D Molecular Therapeutics
9.88
6.27
173.68%
TERN
Terns Pharmaceuticals
52.86
49.76
1605.16%
ERAS
Erasca
15.99
14.51
980.41%
Meiragtx Holdings Corporate Events
Business Operations and StrategyStock Buyback
MeiraGTx Announces Share Repurchase and Investor Lock-Up
Positive
Jan 2, 2026
On December 31, 2025, MeiraGTx Holdings plc agreed to repurchase 2.3 million of its ordinary shares from Perceptive Life Sciences Master Fund, an affiliate of Perceptive Advisors, at $7.91 per share, matching the Nasdaq volume-weighted average pri...
Business Operations and Strategy
MeiraGTx and Eli Lilly Collaborate on Genetic Medicines
Positive
Nov 10, 2025
On November 7, 2025, MeiraGTx entered into a strategic collaboration with Eli Lilly to develop and commercialize genetic medicines in ophthalmology. The agreement grants Lilly exclusive rights to MeiraGTx’s AAV-AIPL1 program, which has shown...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.